Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 05 February, 2002

Xenova Group PLC

Research Update

Xenova Group PLC
5 February 2002

For Immediate Release

                                 Xenova Group plc

              Anti-Cancer Compound XR11576 Enters Clinical Trials



Slough, UK, 5 February 2002 - Xenova Group plc (NASDAQ: XNVA; London Stock
Exchange: XEN) today announced that patient dosing has begun at the University
Hospital of Rotterdam, Rotterdam Cancer Institute with XR11576 (MLN576), a novel
anti-cancer agent.



This open label, Phase I trial is being carried out at centres in the UK and the
Netherlands and comprises multiple ascending oral doses in patients with solid
tumours.  Patients will be monitored for safety, tolerability, pharmacokinetics
and anti-tumour activity.



XR11576 (MLN576) is one of a programme of compounds for the treatment of solid
tumours.  Along with compounds XR5944 (MLN944) and XR11612 (MLN612), XR11576
(MLN576) is the subject of a licence agreement with Millennium Pharmaceuticals
Inc, which was announced in December 2001 for the development and exclusive
North American commercialisation rights to this programme.  The compounds are
believed to be novel DNA targeting agents that affect the DNA replication
process through a mechanism of action which involves the dual inhibition of
topoisomerases I and II.  Xenova retains responsibility for performing
development activities associated with the programme, which will be funded by
Millennium commencing in 2003, to the end of Phase II clinical trials.



David Oxlade, Xenova's Chief Executive, said: 'XR11576 has shown considerable
promise in preclinical studies including good oral bioavailability.  These
compounds have a novel and exciting mechanism of action and have shown
considerable evidence of activity in in vivo xenograft models.  There remains a
clear need in the marketplace for new cytotoxics in order to improve the quality
of treatment and outcomes for a large number of cancer patients.'





Contacts

UK:
Xenova Group plc                                              Financial Dynamics

David Oxlade, Chief Executive Officer                   David Yates/Fiona Noblet
Daniel Abrams, Finance Director                         Tel: +44(0) 207 831 3113
Hilary Reid Evans, Head of Corporate Communications
Tel: +44 (0) 1753 706600



US:
Trout Group/BMC Communications
Press: Brad Miles (Ext 17) Lauren Tortorete (Ext 20)
Investors: Jonathan Fassberg (Ext 16) Lee Stern (Ext 22)
Tel: 001 212 477 9007





Notes to Editors



Xenova Group plc's product pipeline focuses principally on cancer and
immunotherapy.  Xenova currently has a broad pipeline of products in clinical
development.  The multi-drug resistance modulator tariquidar/XR9576, North
American rights for which were licensed to QLT Inc in August 2001, is expected
to enter Phase III clinical trials during the first half of 2002. Two
immunotherapeutic vaccines,TA-HPV and TA-CIN, are undergoing Phase II 
'Prime-Boost' clinical trials in combination for the treatment of ano-genital
dysplasia and a third vaccine, DISC-GMCSF, is being evaluated for the treatment
of malignant melanoma.  In non-cancer related therapy areas, TA-CD, a vaccine
for the treatment of cocaine addiction, is currently undergoing Phase II trials
and  a vaccine for the treatment of nicotine addiction, TA-NIC, is in Phase I
clinical trials.  DISC-PRO, a vaccine for the prevention of herpes, has
completed Phase I trials.  In addition, a product candidate for the prevention
of bovine herpes, DISC-BHV, was entered into development by Xenova's global
partner, Pfizer Animal Health, in January 2001.



The Group has a well-established track record in the identification, development
and partnering of innovative products and technologies and has partnerships with
major pharmaceutical companies including Lilly, Pfizer, Celltech, QLT and
Millennium.



For further information about Xenova and its products please visit the Xenova
website at www.xenova.co.uk



Disclaimer to take advantage of the 'Safe Harbor' provisions of the US Private
Securities Litigation Reform Act of 1995. This press release contains 
'forward-looking statements,' including statements about the discovery,
development and commercialisation of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.



                      This information is provided by RNS
            The company news service from the London Stock Exchange